Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)

Jittamala P., Boyd S., Schilling WHK., Watson JA., Ngamprasertchai T., Siripoon T., Luvira V., Batty EM., Wongnak P., Esper LM., Almeida PJ., Cruz C., Ascencao FR., Aguiar RS., Ghanchi NK., Callery JJ., Singh S., Kruabkontho V., Ngernseng T., Tubprasert J., Madmanee W., Suwannasin K., Promsongsil A., Hanboonkunupakarn B., Poovorawan K., Potaporn M., Srisubat A., Loharjun B., Taylor WRJ., Qamar F., Kazi AM., Beg MA., Chommanam D., Vidhamaly S., Chotivanich K., Imwong M., Pukrittayakamee S., Dondorp AM., Day NPJ., Teixeira MM., Piyaphanee W., Phumratanaprapin W., White NJ.

DOI

10.1101/2024.01.16.24301337

Type

Publication Date

18/01/2024

Permalink Original publication